{"success":true,"data":{"pressRelease":{"id":"41923","rtpr_id":"nACSrYSzFa","ticker":"SATG","exchange":"XETRA","all_tickers":["SATG"],"title":"Sartorius Opens New Competence Center for cell and Gene Therapy Components in Freiburg, Germany","author":"ACCESSWIRE","published_at":"2026-05-21T11:25:00.604Z","article_body":"Sartorius opens new competence center for cell and gene therapy components in\nFreiburg, Germany\n*\nManufacturing capacity for quality-critical materials for the dynamic cell and\ngene therapy market more than doubled\n*\nOpening ceremony in the Haid industrial park with around 180 guests\n*\nTotal investment of more than 140 million euros\n*\nState-of-the-art building technology with no use of fossil fuels\n\nGÖTTINGEN, DE / ACCESS Newswire (https://www.accessnewswire.com/) / May 21,\n2026 / The life science group Sartorius has opened a new competence center in\nFreiburg, Germany, dedicated to the development and production of\nquality-critical materials for the cell and gene therapy market. In Freiburg,\nthe company manufactures essential components such as cytokines and growth\nfactors used in these novel therapies. With an investment of more than 140\nmillion euros, Sartorius is reaffirming its strategic focus on this emerging\nbusiness area. Cell and gene therapies are rapidly gaining importance\nworldwide and already account for around 30 percent of drug development\npipelines.\n\n\"Cell and gene therapies offer patients hope for curing diseases that were\npreviously considered untreatable. Cytokines, growth factors, and cell culture\nmedia are essential for the development and manufacture of these innovative\ntherapies. As a key site in our global network for these critical materials,\nFreiburg serves a dynamic market with high requirements for speed,\nscalability, and process reliability. By significantly expanding our\ncapacities, we can respond much more flexibly to demand from our biopharma\ncustomers and support them even better in bringing cell and gene therapies to\npatients faster and more efficiently,\" said René Fáber, Head of the\nBioprocess Solutions Division and member of the Sartorius Executive Board.\n\nIn the Haid industrial park, state-of-the-art production, laboratory, and\noffice spaces have been created. The site covers approximately 18,000 square\nmeters and can accommodate up to 180 employees. The new facility meets the\nhighest GMP quality standards and thus the stringent requirements of the\nbiopharmaceutical industry. In addition, it operates entirely without fossil\nfuels due to its innovative building technology: Geothermal energy provides\nheating, well water provides cooling, and solar panels generate electricity.\nFor this consistent focus on sustainability, the site has already been\nrecognized with a Gold pre-certification by the German Sustainable Building\nCouncil.\n\n\"The expansion in Freiburg is the result of many years of close and\nconstructive collaboration. We would particularly like to highlight the\nsupport provided by the City of Freiburg and our planning, construction, and\ntechnology partners. Together, we have created a facility that combines\ncutting-edge technology in research and production with sustainability,\" said\nDaniel Spatz, Managing Director of Sartorius CellGenix in Freiburg.\n\nThe opening of the new plant marks an important milestone in the development\nof the Freiburg site. In 2021, Sartorius acquired a majority stake in\nCellGenix GmbH, which was founded in 1994 at the University Medical Center\nFreiburg. The company has been fully integrated into the Sartorius Group since\nearly 2026. Over the past five years, the number of employees in Freiburg has\nnearly doubled to around 140 people.\n\nThe development of the site is part of a long-term investment program aimed at\nexpanding Sartorius's global research and manufacturing network. The objective\nis to prepare the company for further organic growth, strengthen its\nresilience, and continue to ensure high delivery reliability and consistent\nproduct quality across all locations.\n\nFurther information and photos (https://pr.report/lrsg)\n\nA profile of Sartorius\n\nSartorius is a leading international partner to the biopharmaceutical research\nand manufacturing industries. The Lab Products & Services Division focuses on\ninnovative laboratory instruments and consumables for research and quality\nassurance laboratories in pharmaceutical and biopharmaceutical companies as\nwell as academic research institutions. The Bioprocess Solutions Division\nsupports customers with a broad product portfolio focused on single-use\nsolutions for the safer, faster, and more sustainable production of biotech\ndrugs, vaccines, and cell and gene therapies. With around 60 production and\nsales locations worldwide, the Göttingen-based company has a strong global\npresence. Sartorius regularly supplements its portfolio with acquisitions of\ncomplementary technologies. In 2025, the company generated sales revenue of\naround 3.5 billion euros. More than 14,000 employees serve customers around\nthe globe.\n\nVisit our newsroom (https://pr.report/lrsh) or follow Sartorius on LinkedIn\n(https://pr.report/lrsi).\n\nContact\nLeona Malorny\nHead of External Communications\n+49 551 308 4067\nleona.malorny@sartorius.com\n\nAdditional features:\n\nFile: Sartorius opens new competence center for cell and gene therapy\ncomponents in Freiburg, Germany | Media release (https://pr.report/lrsj)\n\nSOURCE: SARTORIUS AG\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/chemicals/sartorius-opens-new-competence-center-for-cell-and-gene-therapy-components-in-freiburg-ge-1169103)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSrYSzFa","title":"Sartorius Opens New Competence Center for cell and Gene Therapy Components in Freiburg, Germany","author":"ACCESSWIRE","ticker":"SATG","created":"2026-05-21T11:25:00.604Z","tickers":["SATG"],"exchange":"XETRA","article_body":"Sartorius opens new competence center for cell and gene therapy components in\nFreiburg, Germany\n*\nManufacturing capacity for quality-critical materials for the dynamic cell and\ngene therapy market more than doubled\n*\nOpening ceremony in the Haid industrial park with around 180 guests\n*\nTotal investment of more than 140 million euros\n*\nState-of-the-art building technology with no use of fossil fuels\n\nGÖTTINGEN, DE / ACCESS Newswire (https://www.accessnewswire.com/) / May 21,\n2026 / The life science group Sartorius has opened a new competence center in\nFreiburg, Germany, dedicated to the development and production of\nquality-critical materials for the cell and gene therapy market. In Freiburg,\nthe company manufactures essential components such as cytokines and growth\nfactors used in these novel therapies. With an investment of more than 140\nmillion euros, Sartorius is reaffirming its strategic focus on this emerging\nbusiness area. Cell and gene therapies are rapidly gaining importance\nworldwide and already account for around 30 percent of drug development\npipelines.\n\n\"Cell and gene therapies offer patients hope for curing diseases that were\npreviously considered untreatable. Cytokines, growth factors, and cell culture\nmedia are essential for the development and manufacture of these innovative\ntherapies. As a key site in our global network for these critical materials,\nFreiburg serves a dynamic market with high requirements for speed,\nscalability, and process reliability. By significantly expanding our\ncapacities, we can respond much more flexibly to demand from our biopharma\ncustomers and support them even better in bringing cell and gene therapies to\npatients faster and more efficiently,\" said René Fáber, Head of the\nBioprocess Solutions Division and member of the Sartorius Executive Board.\n\nIn the Haid industrial park, state-of-the-art production, laboratory, and\noffice spaces have been created. The site covers approximately 18,000 square\nmeters and can accommodate up to 180 employees. The new facility meets the\nhighest GMP quality standards and thus the stringent requirements of the\nbiopharmaceutical industry. In addition, it operates entirely without fossil\nfuels due to its innovative building technology: Geothermal energy provides\nheating, well water provides cooling, and solar panels generate electricity.\nFor this consistent focus on sustainability, the site has already been\nrecognized with a Gold pre-certification by the German Sustainable Building\nCouncil.\n\n\"The expansion in Freiburg is the result of many years of close and\nconstructive collaboration. We would particularly like to highlight the\nsupport provided by the City of Freiburg and our planning, construction, and\ntechnology partners. Together, we have created a facility that combines\ncutting-edge technology in research and production with sustainability,\" said\nDaniel Spatz, Managing Director of Sartorius CellGenix in Freiburg.\n\nThe opening of the new plant marks an important milestone in the development\nof the Freiburg site. In 2021, Sartorius acquired a majority stake in\nCellGenix GmbH, which was founded in 1994 at the University Medical Center\nFreiburg. The company has been fully integrated into the Sartorius Group since\nearly 2026. Over the past five years, the number of employees in Freiburg has\nnearly doubled to around 140 people.\n\nThe development of the site is part of a long-term investment program aimed at\nexpanding Sartorius's global research and manufacturing network. The objective\nis to prepare the company for further organic growth, strengthen its\nresilience, and continue to ensure high delivery reliability and consistent\nproduct quality across all locations.\n\nFurther information and photos (https://pr.report/lrsg)\n\nA profile of Sartorius\n\nSartorius is a leading international partner to the biopharmaceutical research\nand manufacturing industries. The Lab Products & Services Division focuses on\ninnovative laboratory instruments and consumables for research and quality\nassurance laboratories in pharmaceutical and biopharmaceutical companies as\nwell as academic research institutions. The Bioprocess Solutions Division\nsupports customers with a broad product portfolio focused on single-use\nsolutions for the safer, faster, and more sustainable production of biotech\ndrugs, vaccines, and cell and gene therapies. With around 60 production and\nsales locations worldwide, the Göttingen-based company has a strong global\npresence. Sartorius regularly supplements its portfolio with acquisitions of\ncomplementary technologies. In 2025, the company generated sales revenue of\naround 3.5 billion euros. More than 14,000 employees serve customers around\nthe globe.\n\nVisit our newsroom (https://pr.report/lrsh) or follow Sartorius on LinkedIn\n(https://pr.report/lrsi).\n\nContact\nLeona Malorny\nHead of External Communications\n+49 551 308 4067\nleona.malorny@sartorius.com\n\nAdditional features:\n\nFile: Sartorius opens new competence center for cell and gene therapy\ncomponents in Freiburg, Germany | Media release (https://pr.report/lrsj)\n\nSOURCE: SARTORIUS AG\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/chemicals/sartorius-opens-new-competence-center-for-cell-and-gene-therapy-components-in-freiburg-ge-1169103)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-21T11:25:00.623022541Z","server_sent_at_ms":1779362700623},"received_at":"2026-05-21T11:25:00.688Z","source_url":"https://www.accessnewswire.com/newsroom/en/chemicals/sartorius-opens-new-competence-center-for-cell-and-gene-therapy-components-in-freiburg-ge-1169103"},"analysis":{"id":"31361","press_release_id":"41923","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Sartorius opened a new €140 million competence center in Freiburg, Germany, dedicated to producing quality-critical materials for cell and gene therapy.\n\nThe facility, covering 18,000 square meters, more than doubles manufacturing capacity for cytokines and growth factors, addressing the rapid growth of this segment which now accounts for 30% of drug development pipelines.\n\nThe site is fully integrated into the Sartorius Group following the 2021 acquisition of CellGenix GmbH and features fossil-free building technology certified by the German Sustainable Building Council.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Sartorius doubles C&GT capacity with €140M Freiburg facility, betting big on the 30% of pipelines now focused on cell/gene therapies."},"keyFigures":{"customDimensions":{"investment_eur":140000000,"capacity_increase":"more than doubled","current_employees":140,"employee_capacity":180,"facility_size_sqm":18000,"cgt_pipeline_share":"30%"}},"quotedText":"Cell and gene therapies offer patients hope for curing diseases that were previously considered untreatable. Cytokines, growth factors, and cell culture media are essential for the development and manufacture of these innovative therapies.","namedEntities":{"people":[{"name":"René Fáber","role":"Head of Bioprocess Solutions Division, Executive Board"},{"name":"Daniel Spatz","role":"Managing Director, Sartorius CellGenix"},{"name":"Leona Malorny","role":"Head of External Communications"}],"products":["cytokines","growth factors","cell culture media"],"companies":[{"name":"Sartorius","ticker":"SATG","relationship":"filer"},{"name":"CellGenix GmbH","relationship":"subsidiary"},{"name":"University Medical Center Freiburg","relationship":"partner"},{"name":"City of Freiburg","relationship":"partner"},{"name":"German Sustainable Building Council","relationship":"certifier"}],"dollarAmounts":[{"amount":"140 million euros","context":"total investment in new competence center"},{"amount":"3.5 billion euros","context":"2025 sales revenue"}]},"materialImpact":{"score":3,"reasoning":"A €140M capital investment in a new facility for a high-growth segment (cell and gene therapy) signals strategic commitment and capacity expansion. It is a significant operational milestone but not a binary event like M&A or FDA approval."},"tickerRelevance":{"others":[],"primary":"SATG"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"capex_expansion","sectorWeight":"high_growth_biotech_supplies","householdBrandBoost":"low","marketCapAdjustment":"neutral"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Sartorius opened a new €140 million competence center in Freiburg, Germany, dedicated to producing quality-critical materials for cell and gene therapy.\n\nThe facility, covering 18,000 square meters, more than doubles manufacturing capacity for cytokines and growth factors, addressing the rapid growth of this segment which now accounts for 30% of drug development pipelines.\n\nThe site is fully integrated into the Sartorius Group following the 2021 acquisition of CellGenix GmbH and features fossil-free building technology certified by the German Sustainable Building Council.","key_figures":{"customDimensions":{"investment_eur":140000000,"capacity_increase":"more than doubled","current_employees":140,"employee_capacity":180,"facility_size_sqm":18000,"cgt_pipeline_share":"30%"}},"named_entities":{"people":[{"name":"René Fáber","role":"Head of Bioprocess Solutions Division, Executive Board"},{"name":"Daniel Spatz","role":"Managing Director, Sartorius CellGenix"},{"name":"Leona Malorny","role":"Head of External Communications"}],"products":["cytokines","growth factors","cell culture media"],"companies":[{"name":"Sartorius","ticker":"SATG","relationship":"filer"},{"name":"CellGenix GmbH","relationship":"subsidiary"},{"name":"University Medical Center Freiburg","relationship":"partner"},{"name":"City of Freiburg","relationship":"partner"},{"name":"German Sustainable Building Council","relationship":"certifier"}],"dollarAmounts":[{"amount":"140 million euros","context":"total investment in new competence center"},{"amount":"3.5 billion euros","context":"2025 sales revenue"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-21T11:25:11.939Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"large-cap","eventGravity":"capex_expansion","sectorWeight":"high_growth_biotech_supplies","householdBrandBoost":"low","marketCapAdjustment":"neutral"}},"durationMs":11227,"modelName":"george-droid-qwen-72b"}}